In recent years, immunotherapy, represented by PD-L1/PD-1 inhibitors, has developed rapidly, leading to a greatly improved prognosis for patients with non-small-cell lung cancer (NSCLC) without targetable oncogene alterations (1–4). This evidence concerns the gene CD274 and non-small cell lung carcinoma.